Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2003
06/26/2003WO2003051840A1 Pyrrolidine and piperidine derivates as nk1 antagonists
06/26/2003WO2003051838A2 Protein kinase inhibitors
06/26/2003WO2003051837A2 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
06/26/2003WO2003051836A1 Prodrugs to d-prolines
06/26/2003WO2003051833A2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
06/26/2003WO2003051831A2 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
06/26/2003WO2003051828A2 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
06/26/2003WO2003051827A1 Process for the preparation of an enantiomerically enriched thio compound
06/26/2003WO2003051826A1 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
06/26/2003WO2003051825A1 Human adam-10 inhibitors
06/26/2003WO2003051822A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003WO2003051821A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003WO2003051819A1 Substituted 1,5-diaminopentan-3-ol compounds
06/26/2003WO2003051818A1 A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochloride polymorphs and amorphous form
06/26/2003WO2003051807A2 Improvements in pharmaceutical compositions
06/26/2003WO2003051806A1 Antibacterial compounds
06/26/2003WO2003051805A2 Substituted phenyl naphthalenes as estrogenic agents
06/26/2003WO2003051804A1 Novel substance having antitumor/anti-inflammatory activity
06/26/2003WO2003051458A1 Superoxide dismutase mimics for the treatment of ocular disorders and diseases
06/26/2003WO2003051454A2 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
06/26/2003WO2003051400A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003WO2003051398A1 Parenteral composition of paracetamol
06/26/2003WO2003051397A1 Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia
06/26/2003WO2003051396A1 Treating vascular disease by inhibiting myeloid differentiation factor 88
06/26/2003WO2003051395A2 Edg-receptor agonist for the treatment of hypertension
06/26/2003WO2003051388A2 Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
06/26/2003WO2003051385A1 Pharmaceutical formulation comprising cyclosporin and use thereof
06/26/2003WO2003051384A1 Method for treating cervical cancer
06/26/2003WO2003051383A2 Use of hmgb proteins and nucleic acids that code therefor
06/26/2003WO2003051382A1 Method of inducing apoptosis and compositions therefor
06/26/2003WO2003051380A2 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders
06/26/2003WO2003051376A1 Chitosan oligosaccharides and uses thereof
06/26/2003WO2003051375A1 Stabilized brivudine topical formulations
06/26/2003WO2003051374A2 SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
06/26/2003WO2003051373A1 Liquid bisphosphonate formulations for bone disorders
06/26/2003WO2003051372A1 Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
06/26/2003WO2003051371A1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
06/26/2003WO2003051370A1 Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction
06/26/2003WO2003051369A1 Pharmaceutical containing n, n'-disubstituted piperazine compounds
06/26/2003WO2003051367A1 Parental analgesic formulations comprising fentanyl and a cannabinoid receptor agonist
06/26/2003WO2003051365A2 Use of compounds of the benzamide family as immunosuppressant
06/26/2003WO2003051364A1 Amlopidine bezylate tablets with improved stability
06/26/2003WO2003051363A1 Analgesic delivery systems and methods of use
06/26/2003WO2003051362A2 Polymorphs of clopidogrel hydrogensulfate
06/26/2003WO2003051361A1 Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
06/26/2003WO2003051360A1 Cis-imidazolines as mdm2 inhibitors
06/26/2003WO2003051359A1 Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
06/26/2003WO2003051358A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/26/2003WO2003051357A1 Glucagon receptor antagonists/inverse agonists
06/26/2003WO2003051356A1 Method for treating circadian rhythm disruptions
06/26/2003WO2003051355A1 Solid compositions containng compounds unstable to oxygen and method for stabilization thereof
06/26/2003WO2003051354A1 Method of treatment
06/26/2003WO2003051353A1 Substituted beta-aminoalcohols used as medicaments
06/26/2003WO2003051352A1 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
06/26/2003WO2003051351A1 Ophthalmic rofecoxib suspension for the treatment of ocular pain and inflammation
06/26/2003WO2003051350A1 Use of lipoxin analogs to promote cell defense against gram-negative infections
06/26/2003WO2003051349A1 Method of treating iron overload
06/26/2003WO2003051348A2 Composition, synthesis and therapeutic applications of polyamines
06/26/2003WO2003051347A1 Use of urokinase receptor antagonists to modulate ischemiareperfusion injury
06/26/2003WO2003051346A2 Use of selective pde5 inhibitors for treating partial and global respiratory failure
06/26/2003WO2003051344A1 Methods of inducing ovulation_using a non-polypeptide camp level modulator
06/26/2003WO2003051342A1 Compressed oral pharmaceutical dosage form, with an enteric coating, which contains an acid-labile benzimidazole compound
06/26/2003WO2003051341A1 Dosage form for providing time-varying patterns of drug delivery
06/26/2003WO2003051340A1 New film coating
06/26/2003WO2003051338A1 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
06/26/2003WO2003051337A1 Pre-formulation for the tabletting of natural mixtures of conjugated estrogens
06/26/2003WO2003051336A1 Matrix film tablets for the controlled release of natural mixtures of conjugated estrogen
06/26/2003WO2003051334A2 Pharmaceutical composition comprising an oil/water/oil double microemulsion incorporated into a solid support
06/26/2003WO2003051333A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/26/2003WO2003051315A2 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
06/26/2003WO2003051313A2 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
06/26/2003WO2003051307A2 Materials and methods for the treatment or prevention of obesity
06/26/2003WO2003051306A2 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
06/26/2003WO2003051304A2 Bioadhesive drug delivery system with enhanced gastric retention
06/26/2003WO2003051303A2 The total synthesis of merrilactone a
06/26/2003WO2003051302A2 Methods and compositions for treatment of central nervous system disorders
06/26/2003WO2003051301A2 USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
06/26/2003WO2003051300A2 Metal complexes and formulations of rifamycin analogues and uses therof
06/26/2003WO2003051299A2 Sulfhydryl rifamycins and uses thereof
06/26/2003WO2003051297A2 Aqueous ifosfamide composition
06/26/2003WO2003051296A2 Improved skin barrier function and cohesion through enhanced stratum corneum acidification
06/26/2003WO2003051295A2 Neutralization of stratum corneum to treat hyperkeratotic skin lesions
06/26/2003WO2003051294A2 Mitocidal compositions and methods
06/26/2003WO2003051293A2 Antidiabetic formulation and method
06/26/2003WO2003051292A2 Novel topical pharmaceutical base with anti-pruritic and/or anti-inflammatory drugs
06/26/2003WO2003051289A2 Solubilized topoisomerase poison agents
06/26/2003WO2003051287A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003WO2003051281A2 Composition and method to treat viral bacterial and parasitic infections and infestations
06/26/2003WO2003051278A2 Nanoparticle delivery vehicle
06/26/2003WO2003051277A2 Novel compounds
06/26/2003WO2003051276A2 Therapeutic heterocycles
06/26/2003WO2003051273A2 Dermal cholic acid as anti-inflammatory and theraputic agent
06/26/2003WO2003051180A2 METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS USING 252, 304, 19870, 14717, 9941, 19310 and 17832
06/26/2003WO2003051126A1 Adhesion inhibition of moulds
06/26/2003WO2003051125A1 Adhesion inhibition of fungi
06/26/2003WO2003051124A2 Inhibition of the asexual reproduction of fungi
06/26/2003WO2003051114A1 Shelf life extension of microemulsions containing active aza biocide
06/26/2003WO2003051113A1 Methods and compositions for controlled release of drugs
06/26/2003WO2003040109A3 Quinazoline derivatives as antitumor agents
06/26/2003WO2003032896A3 Dexibuprofen-containing soft gelatin capsules and process for preparing the same
1 ... 5423 5424 5425 5426 5427 5428 5429 5430 5431 5432 5433 5434 5435 5436 5437 5438 5439 5440 5441 5442 5443 ... 7860